GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT01852565
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of ASA (Acetylsalicylic Acid) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fasting Conditions
- Conditions
- Ulcers, Duodenal and Gastric
- Interventions
- First Posted Date
- 2013-05-06
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT01847404
- Locations
- 🇮🇳
GSK Investigational Site, Hyderabad, India
Comparison of Pharmacokinetic Profiles of Two Nicotine Gum Formulations
- First Posted Date
- 2013-05-06
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 84
- Registration Number
- NCT01847443
- Locations
- 🇬🇧
Celerion - BELFAST, Belfast, Northern Ireland, United Kingdom
Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fed Conditions
- Conditions
- Ulcers, Duodenal and Gastric
- Interventions
- First Posted Date
- 2013-05-06
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT01847417
- Locations
- 🇮🇳
GSK Investigational Site, Hyderabad, India
Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder
- Conditions
- Hepatitis B
- Interventions
- Biological: Engerix™-B Kinder
- First Posted Date
- 2013-05-06
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 303
- Registration Number
- NCT01847430
- Locations
- 🇩🇪
GSK Investigational Site, Neumuenster, Germany
Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache
- Conditions
- Pain
- Interventions
- First Posted Date
- 2013-04-29
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 365
- Registration Number
- NCT01842633
- Locations
- 🇺🇸
PAREXEL International, LLC, Waltham, Massachusetts, United States
OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck.
- First Posted Date
- 2013-04-29
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT01842620
A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects
- Conditions
- Asthma
- Interventions
- Biological: Mepolizumab
- First Posted Date
- 2013-04-29
- Last Posted Date
- 2018-08-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 651
- Registration Number
- NCT01842607
- Locations
- 🇬🇧
GSK Investigational Site, Southampton, United Kingdom
Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients
- Conditions
- Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Other: Data acquisition and analysis
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2013-04-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 377
- Registration Number
- NCT01837511
- Locations
- 🇸🇬
GSK Investigational Site, Singapore, Singapore
A Study to Assess the Bronchodilator Effect of a Single Dose of Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 Micrograms (mcg) Combination When Administered in Adult Patients With Asthma
- Conditions
- Asthma
- Interventions
- Drug: PlaceboDrug: FF/VI 100/25 mcg
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT01837316
- Locations
- 🇳🇿
GSK Investigational Site, Wellington, New Zealand